MedPath

Fluor Varnish With Silver Nanoparticles for Dental Remineralization in Patients With Trisomy 21

Phase 2
Conditions
Down Syndrome
Interventions
Drug: Fluor varnish
Drug: Fluor varnish with nanoparticles
Registration Number
NCT01975545
Lead Sponsor
Universidad Autonoma de San Luis Potosí
Brief Summary

Patients with trisomy 21 are in greater danger of developing caries. It has been hypothesized that adding silver nanoparticles to fluor varnishes could promote remineralization of the teeth. A split-plot randomized controlled trial will be performed to address this question.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Patients with trisomy 21 diagnosed through caryotype
  • Age 1 to 6 years old
  • Any sex
  • White spot present in both upper anterior teeth
  • Parental agreement to participate in the study
Exclusion Criteria
  • Hypersensibility to any of the substances used
  • Non cooperating patients
  • Caries in enamel or dentine in the upper anterior teeth
  • Leukemia or diabetes
  • Dental fluorosis present

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Fluor varnishFluor varnishFluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein)
Fluor varnish with nanoparticlesFluor varnish with nanoparticlesFluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein) plus 25% 50 nm silver nanoparticles.
Primary Outcome Measures
NameTimeMethod
Remineralization3 months

Remineralization status will be assessed through laser fluorescence of the tooth with a Diagnodent probe (Diagnodent, Kavo, Madrid, Spain)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Universidad Autónoma de San Luis Potosí

🇲🇽

San Luis Potosí, Mexico

© Copyright 2025. All Rights Reserved by MedPath